Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Recommendation of "Buy" by Analysts

Market Beat
2025.02.17 07:17
portai
I'm PortAI, I can summarize articles.

Spyre Therapeutics, Inc. (NASDAQ:SYRE) has received a consensus "Buy" rating from seven brokerages. The average 12-month price target is $54.83, with recent upgrades from Robert W. Baird and Guggenheim raising their targets to $65.00. Institutional investors hold 80.39% of the stock, which opened at $22.92, with a 52-week range of $20.07 to $47.97. Spyre focuses on developing therapeutics for inflammatory bowel disease, specifically SPY001, a monoclonal antibody for ulcerative colitis and Crohn's disease.

Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) has received a consensus rating of "Buy" from the seven brokerages that are currently covering the company, Marketbeat reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $54.83.

Get Spyre Therapeutics alerts:

Several brokerages have recently weighed in on SYRE. Robert W. Baird upped their target price on shares of Spyre Therapeutics from $50.00 to $65.00 and gave the company an "outperform" rating in a research note on Wednesday, November 13th. Guggenheim raised their target price on Spyre Therapeutics from $50.00 to $65.00 and gave the company a "buy" rating in a research note on Friday, October 25th. Finally, Wedbush reiterated an "outperform" rating and issued a $65.00 price target on shares of Spyre Therapeutics in a research note on Monday, January 13th.

Read Our Latest Report on SYRE

Institutional Investors Weigh In On Spyre Therapeutics

A number of institutional investors have recently modified their holdings of SYRE. Huntington National Bank bought a new position in Spyre Therapeutics in the 4th quarter worth approximately $34,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Spyre Therapeutics in the fourth quarter worth about $46,000. Quest Partners LLC increased its stake in Spyre Therapeutics by 271.2% during the 3rd quarter. Quest Partners LLC now owns 5,654 shares of the company's stock valued at $166,000 after buying an additional 4,131 shares during the period. KLP Kapitalforvaltning AS bought a new stake in shares of Spyre Therapeutics during the 4th quarter worth about $182,000. Finally, Intech Investment Management LLC acquired a new stake in shares of Spyre Therapeutics in the 3rd quarter worth approximately $246,000. Institutional investors own 80.39% of the company's stock.

Spyre Therapeutics Trading Up 1.1 %

Shares of SYRE stock opened at $22.92 on Monday. Spyre Therapeutics has a 52 week low of $20.07 and a 52 week high of $47.97. The company has a market cap of $1.18 billion, a PE ratio of -3.07 and a beta of 2.85. The company's fifty day simple moving average is $23.11 and its 200-day simple moving average is $27.13.

About Spyre Therapeutics

(Get Free Report

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).

Featured Articles

  • Five stocks we like better than Spyre Therapeutics
  • Insider Selling Explained: Can it Inform Your Investing Choices?
  • Symbotic Shares Down 37%—Is It Time for Bravery or Caution?
  • 3 Natural Gas Stocks That Offer Great Dividend Yields
  • High-Yield Healthcare: 3 Stocks With Strong Dividends
  • Stock Splits, Do They Really Impact Investors?
  • Beyond the Bargain Bin: 3 Stocks Leading Discount Retail

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Where Should You Invest $1,000 Right Now?

Before you make your next trade, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.

Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.

They believe these five stocks are the five best companies for investors to buy now...

See The Five Stocks Here

Should You Invest $1,000 in Spyre Therapeutics Right Now?

Before you consider Spyre Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spyre Therapeutics wasn't on the list.

While Spyre Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Source: Market Beat The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.